OVARIAN CANCER

This early-stage trial tested the safety and best dose of a new drug, STRO-002, when given with an existing cancer drug, bevacizumab. It was for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that had come back or stopped responding to standard treatme…

This early-stage study tested the safety and highest tolerable dose of an experimental drug called INCB062079 in people with advanced liver cancer and other solid tumors. The trial enrolled 25 participants whose cancers had progressed after standard treatments and was designed to…

This study tested whether combining two targeted drugs, alpelisib and olaparib, works better than standard chemotherapy for women with a specific type of advanced ovarian cancer that has stopped responding to platinum-based treatments. The trial enrolled 358 women whose cancer ha…

This early-stage study tested a new oral cancer drug called NUV-868, both alone and combined with existing medications (olaparib or enzalutamide), in adults with advanced solid tumors. The trial aimed to find safe doses and see if these treatments could help control cancers that …

This study tested whether adding an experimental drug called SOT101 to an existing immunotherapy (pembrolizumab) could help control advanced cancers that had stopped responding to other treatments. It involved 166 adults with specific advanced solid tumors, including lung, colore…

This early-stage study aimed to test the safety and find the right dose of a new drug called BLU-222 for people with advanced solid tumors that have stopped responding to standard treatments. It involved about 50 patients with cancers like breast, ovarian, and gastric cancer. The…

This early-stage study tested a new radioactive drug designed to target and destroy advanced solid tumors. It involved 78 patients with various cancers who had run out of standard treatment options. The main goals were to check the treatment's safety, find the right dose, and see…

This early-stage study tested a personalized cancer treatment that modifies a patient's own immune cells to recognize and attack their specific tumor mutations. The trial enrolled 8 adults with advanced solid tumors (including ovarian, lung, pancreatic, and colorectal cancers) wh…

This was an early-stage study testing a new drug called BDC-3042, both by itself and combined with an existing immunotherapy (cemiplimab), in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find safe doses and see if the tre…

This early-phase study tested a new drug called PRO1107 in patients with advanced solid tumors that had stopped responding to other treatments. The main goals were to find a safe dose and see if the drug could shrink tumors in cancers like ovarian, lung, breast, and others. The s…

This early-stage study tested a new treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned or stopped responding to standard therapies. Researchers collected a patient's own immune cells (monocytes), activated them with two drugs…

This early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…

This early-stage study tested a new drug called OC-001, both by itself and combined with an existing immunotherapy drug, in people with various advanced cancers that had stopped responding to standard treatments. The main goal was to check the safety of the drug and see how the b…

This first-in-human study tested a new cancer drug called PHN-010 in patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, determine the right dose, and see if it could shrink tumors. The trial incl…

This study tested an experimental drug called luveltamab tazevibulin against standard chemotherapy for women with advanced ovarian cancer that had returned and stopped responding to platinum-based drugs. It aimed to see if the new drug could better control the cancer and improve …

This study tested whether combining two existing drugs, copanlisib and fulvestrant, could help control advanced endometrial or ovarian cancers that are hormone-sensitive and have specific genetic changes. The trial aimed to find a safe dose and see if the combination could shrink…

This study aimed to collect fluid samples from the abdomen or chest and blood from adults with solid tumors. The goal was to analyze these samples to better understand cancer biology. Researchers hoped this knowledge would help develop improved cancer treatments in the future. No…